



Biocon Limited
20th KM, Hosur Road
Electronic City
Bangalore 560 100, India
T 91 80 2808 2808
F 91 80 2852 3423

CIN : L24234KA1978PLC003417

www.biocon.com

May 26, 2021

To The Manager BSE Limited Department of Corporate Services Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001 Scrip Code- 532523	To The Manager, National Stock Exchange of India Limited Corporate Communication Department Exchange Plaza, Bandra Kurla Complex Mumbai – 400 050 Scrip Symbol- Biocon
--	--

Subject: Disclosure of Related Party Transactions pursuant to Regulation 23(9) of SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015 ('SEBI Listing Regulation').

Dear Sir/Madam

In Compliance with Regulation 23(9) of SEBI Listing Regulations, please find enclosed disclosure of related party transactions on consolidated basis for the half year ended March 31, 2021, drawn in accordance with applicable accounting standard.

The above information will also be available on the website of the Company at www.biocon.com.

Kindly take on record the above information and acknowledge.

Thanking You,

Yours faithfully,

For **Biocon Limited**

Mayank Verma
Company Secretary and Compliance Officer

Disclosure of related party transactions- On consolidated basis

In pursuance with Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements) (Amendments) Regulations, 2018
(All amounts are in Indian Rupees Million)

Name of related parties	Nature of relationship
Key management personnel	
Kiran Mazumdar-Shaw	Executive Chairperson
Siddharth Mittal	Managing Director & CEO
Indranil Sen	Interim Chief Financial Officer (w.e.f May 15, 2020 , upto September 22, 2020)
Anupam Jindal	Chief Financial Officer (w.e.f April 28, 2021)#
Mayank Verma	Chief Financial Officer (w.e.f September 22, 2020 upto April 28,2021)#
Daniel M Bradbury	Company Secretary
Mary Harney	Independent director
Vijay K Kuchroo	Independent director
M Damodaran	Independent director
Bobby K Parikh	Independent director
John Shaw	Non-executive director
Ravi Mazumdar	Non-executive director
Associate	
Bicara Therapeutics Inc.	Associate (w.e.f. January 09, 2021)
Joint Ventures	
NeoBiocon FZ.LLC	Joint-venture
Other related parties	
Biocon Foundation	Trust in which key management personnel are the Board of Trustees
Immuneel Therapeutics Private Limited	Enterprise in which a director of the Company is a member of board of directors
Mazumdar Shaw Medical Foundation	Trust in which key management personnel are the Board of Trustees
Glentec International Limited	Enterprise owned by key management personnel
Catherine Rosenberg	Relative of a director
Claire Mazumdar	Relative of a director
Jeeves	Enterprise in which relative to a director of the Company is proprietor
Narayana Hrudayalaya Limited	Enterprise in which a director of the Company is a member of board of directors

The Group has the following related party transactions

Particulars	Transactions / Balances	Half year ended March 31, 2021
Key management personnel	Salary and perquisites [refer note (a) & (b) below]	46
	Sitting fees and commission	27
	Outstanding as at the year end:	
	- Trade and other payables	4
Associate	Cross charges towards facility and other expenses	381
	Interest income	2
	Outstanding as at the year end:	
	- Trade and other receivables	660
Joint Venture	Purchase of goods	87
	Sales promotion expenses	4
	Rent expenses	1
	Professional charges	22
	Expenses incurred on behalf of the related party	1
	Outstanding as at the year end:	
	- Trade and other receivables	.*
	- Trade and other payables	363
Other related parties	Sale of goods	33
	Sale of services	2
	Salary and perquisites (includes sitting fees)	58
	Health services availed	3
	Allotment of equity shares	100
	CSR Expenditure	51
	Other expenses	22
	Outstanding as at the year end:	
	- Trade and other receivables	20
	- Trade and other payables	5

* Amounts are not represented since the amounts are rounded off to Rupees million.

Indranil Sen was appointed as the Chief Financial Officer of Biocon Limited effective from April 28, 2021 and Anupam Jindal resigned as Chief Financial Officer w.e.f April 28, 2021.

- (a) The remuneration to key managerial personnel does not include the provisions made for gratuity and compensated absences, as they are obtained on an actuarial basis for the Company as a whole.
- (b) Share-based compensation expense allocable to key management personnel is Rs 34 which is not included in the remuneration disclosed above. Share-based compensation expense allocable to key management personnel issued by foreign associate is Rs 7 which is not included in the remuneration disclosed above.
- (c) The above disclosures include related parties as per Ind AS 24 on "Related Party Disclosures" and Companies Act, 2013.
- (d) All transactions with these related parties are priced on an arms length basis and none of the balances are secured.

